盆腔实体瘤中18F-FDG PET/CT与PET/MRI测量重复性比较
该前瞻性研究纳入14例病理证实的盆腔恶性肿瘤患者,在一次注射370 MBq 18F-FDG后依次行PET/CT和PET/MRI,并在7天内重复相同方案。结果显示PET/MRI的SUVmax和SULpeak重测变异系数与PET/CT无显著差异,ADC中位值的变异系数为3.5%,支持PET/MRI用于定量肿瘤疗效评估。
要点
- 盆腔实体瘤中PET/MRI的SUVmax重测变异系数为6.6%–8.7%,与PET/CT无显著差异。
- PET/MRI的ADC中位值变异系数为3.5%,低于SUV指标但差异无统计学意义。
- 研究支持18F-FDG PET/MRI用于定量肿瘤治疗反应评估。
核心结论
- 盆腔实体瘤中18F-FDG PET/MRI的SUV和ADC指标重测重复性可接受,且与既往PET/CT和MRI报道值相似。
研究设计与样本
- 前瞻性研究纳入14例病理证实的盆腔恶性肿瘤患者,单次注射370 MBq 18F-FDG后依次行PET/CT和PET/MRI,7天内重复相同方案。
主要发现
- PET/CT的SUVmax重测变异系数为8.5%–12.8%,PET/MRI为6.6%–8.7%,两模态无显著重复性差异(所有P值≥0.08)。
- PET/CT的SULpeak重测变异系数为9.9%–11.5%,PET/MRI为9.2%–11.3%,两模态无显著重复性差异(所有P值≥0.14)。
- PET/MRI的ADC中位值重测变异系数为3.5%,低于SUVmax和SULpeak,但无显著重复性差异(所有P值≥0.23)。
临床怎么用
- 在盆腔实体瘤的定量疗效评估中,可考虑使用18F-FDG PET/MRI测量SUV和ADC指标,其重复性与PET/CT相当。
局限性
- 研究样本量较小(14例),且以宫颈癌为主(11例),结论推广需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Knowledge of the within-subject variability of 18F-FDG PET/MRI measurements is necessary for proper interpretation of quantitative PET or MRI metrics in the context of therapeutic efficacy assessments with integrated PET/MRI scanners. The goal of this study was to determine the test-retest repeatability of these metrics on PET/MRI, with comparison to similar metrics acquired by PET/CT. Methods: This prospective study enrolled subjects with pathology-proven pelvic malignancies. Baseline imaging consisted of PET/CT immediately followed by PET/MRI, using a single 370-MBq 18F-FDG dose. Repeat imaging was performed within 7 d using an identical imaging protocol, with no oncologic therapy between sessions. PET imaging on both scanners consisted of a list-mode acquisition at a single pelvic station. The MRI consisted of 2-point Dixon imaging for attenuation correction, standard sequences for anatomic correlation, and diffusion-weighted imaging. PET data were statically reconstructed using various frame durations and minimizing uptake time differences between sessions. SUV metrics were extracted for both PET/CT and PET/MRI in each imaging session. Apparent diffusion coefficient (ADC) metrics were extracted for both PET/MRI sessions. Results: The study cohort consisted of 14 subjects (13 female, 1 male) with various pelvic cancers (11 cervical, 2 rectal, 1 endometrial). For SUVmax, the within-subject coefficient of variation (wCV) appeared higher for PET/CT (8.5%-12.8%) than PET/MRI (6.6%-8.7%) across all PET reconstructions, though with no significant repeatability differences (all P values ≥ 0.08) between modalities. For lean body mass-adjusted SUVpeak, the wCVs appeared similar for PET/CT (9.9%-11.5%) and PET/MRI (9.2%-11.3%) across all PET reconstructions, again with no significant repeatability differences (all P values ≥ 0.14) between modalities. For PET/MRI, the wCV for ADCmedian of 3.5% appeared lower than the wCVs for SUVmax (6.6%-8.7%) and SULpeak (9.2%-11.3%), though without significant repeatability differences (all P values ≥ 0.23). Conclusion: For solid tumors of the pelvis, the repeatability of the evaluated SUV and ADC metrics on 18F-FDG PET/MRI is both acceptably high and similar to previously published values for 18F-FDG PET/CT and MRI, supporting the use of 18F-FDG PET/MRI for quantitative oncologic treatment response assessments.
引用
- Fraum TJ, Fowler KJ, Crandall JP, et al. Measurement Repeatability of 18F-FDG PET/CT Versus 18F-FDG PET/MRI in Solid Tumors of the Pelvis. J Nucl Med. 2019. PMID: 30733325. doi:10.2967/jnumed.118.218735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。